FGF3, fibroblast growth factor 3, 2248

N. diseases: 200; N. variants: 14
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.600 Biomarker disease BEFREE Taken together, these results demonstrated that the peptide FP16, acting as an FGF3 antagonist, is a promising therapeutic agent for the treatment of breast cancer. 26323695 2015
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.600 Biomarker disease BEFREE Thus, to develop a humanized model of MMTV signaling, we over-expressed WNT1 and FGF3 in MCF7 cells, an ER(+) human breast cancer cell line. 26421711 2015
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.600 GeneticVariation disease BEFREE Therefore, in this study, locus 11q13 and FGF3 gene (11q13) function were investigated in a radiation and estrogen breast cancer model induced by high-LET (α-particle) radiation and estrogen exposure. 25333703 2014
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.600 Biomarker disease BEFREE When qPCR-identified amplifications in FGFR1, FGFR2, or FGF3 were grouped to define an FGF pathway-amplified breast cancer in HR-positive patients, the mean reduction in target lesions was 21.1% compared with a 12.0% increase in patients who did not present with FGF pathway-amplified breast cancer. 23658459 2013
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.600 Biomarker disease CTD_human Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. 21936542 2011
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.600 Biomarker disease BEFREE The CCND1-FGF19-FGF4-FGF3 gene cluster in human chromosome 11q13 is amplified in breast cancer, squamous cell carcinoma of head and neck, and bladder tumors, and is also translocated in parathyroid tumors and B-cell lymphoma. 12429977 2002
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.600 Biomarker disease BEFREE Int-2 was amplified in 22% (96/440) of the primary breast carcinomas. 11445874 2001
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.600 Biomarker disease BEFREE Amplification and expression of these genes is particularly interesting in the context of oncovirus involvement, because INT2 is a homolog of mouse int2 which causes mammary carcinoma in mice when activated by integration of retrovirus mouse mammary tumor virus. 10786811 2000
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.600 GeneticVariation disease BEFREE Infrequent (< or =12%) or absent LOH was detected at the remaining loci, including several loci commonly mutated in breast cancer (i.e., INT2, PYGM, and NM23). 10619258 1999
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.600 Biomarker disease BEFREE EMS1 amplification can occur independently of CCND1 or INT-2 amplification at 11q13 and may identify different phenotypes in primary breast cancer. 9380415 1997
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.600 Biomarker disease BEFREE A rapid, non-radioactive approach based on qdPCR and fluorescent DNA technique was applied for determination of int-2 and c-erbB2 gene amplification and correlated with other prognostic factors in 70 breast cancer samples. 9329619 1997
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.600 AlteredExpression disease BEFREE Other members of the fibroblast growth factor family have been either not expressed in the human breast (FGF3, FGF4) or have been found at much reduced levels in breast cancer (FGF1, FGF2) and this is the first member of the family to potentially influence the progression of breast cancer through stimulation of cell division. 9184170 1997
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.600 Biomarker disease BEFREE int-2 oncogene amplification and prognosis in node-negative breast carcinoma. 9421359 1997
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.600 Biomarker disease BEFREE After a median follow-up period of 66 months, CCND1 or INT-2 amplification was not associated with significant increases in relapse or death from breast cancer. 9816285 1996
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.600 Biomarker disease BEFREE To attain this goal, amplification of different oncogenes (HER-2/neu, c-MYC and INT-2) was studied in primary tumors of a series of 259 patients with breast cancer (median follow-up of 72 mo). 7607564 1995
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.600 GeneticVariation disease BEFREE Genetic alterations have been described in breast carcinomas under the headings of loss of heterozygosity (1p, 3p, 7q, 11p, 17p, 17 and 18q), mutations (p53, c-H-ras-1), and/or gene amplifications (c-myc, int-2/FGF3, and c-erbB-2/neu). 7671254 1995
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.600 Biomarker disease BEFREE Breast cancer: prognostic significance of c-erb-B2 and int-2 amplification compared with DNA ploidy, S-phase fraction, and conventional clinicopathological features. 7914106 1994
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.600 Biomarker disease BEFREE Int-2/FGF3 amplification is a better independent predictor of relapse than c-myc and c-erbB-2/neu amplifications in primary human breast cancer. 7892157 1994
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.600 Biomarker disease BEFREE This is the first report of an association between amplification of the int-2 oncogene in breast tumours and a significantly increased risk of death from breast cancer, and suggests that int-2 may be useful for identifying breast-cancer patients having a poor prognosis. 8449602 1993
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.600 GeneticVariation disease BEFREE Sequence analysis of the int-2/fgf-3 gene in aggressive human breast carcinomas. 1362493 1992
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.600 Biomarker disease BEFREE The glutathione S-transferase gene (GST pi) is located on the same chromosome band (11q13) as proto-oncogenes INT2 and HSTF1 which are frequently amplified in breast cancer. 1826346 1991
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.600 AlteredExpression disease BEFREE The c-myc, c-erbB-2, hst and int-2 oncogenes are frequently amplified and/or overexpressed in human breast carcinomas. 1707153 1991
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.600 GeneticVariation disease BEFREE We conclude that, compared to amplification of HER2/NEU, MYC, or INT2 oncogene loci, p53 gene mutations and deletions are the most frequently observed genetic change in breast cancer related to a single gene. 1961733 1991
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.600 Biomarker disease BEFREE Patients with INT2/HST1 amplified breast cancer had a significantly shorter disease-free survival compared to those with unamplified genes (P = 0.015, median follow up 45 months). 1989653 1991
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.600 Biomarker disease BEFREE Analysis of the int-1, int-2, c-myc, and neu oncogenes in human breast carcinomas. 1975511 1990